Third, in the hsBCL9CT-24 treated CT26/MC38 model, hsBCL9CT-24, which is a BCL9 and β-cat inhibitor, suppressed transcription of Wnt signaling both in immune cells and cancer cells, without depleting or knockout BCL9 and β-cat protein. Here, BCL9 is linked to cancer.